SAN DIEGO, Sept. 21, 2006 (PRIMEZONE) -- SmallCapInsights.com, a leading investment newsletter committed to discovering tomorrow's smallcap breakthroughs, has announced the online release of an audio interview following a new installment of compensated coverage of Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs.
The audio interview, hosted by SmallCapInsights.com, provides investment-oriented commentary from Auriga's Chief Executive Officer Philip S. Pesin. Mr. Pesin answered questions regarding Auriga's recently acquired exclusive license to market the FDA-cleared Aquoral(tm), a prescription-only product designed to treat the widespread condition xerostomia, representing a potential marketplace estimated at more than $1 billion, according to the Oral Cancer Foundation. Aquoral(tm) is an innovative integrated spray device containing a proprietary formulation.
"Monday's substantive product announcement details yet another significant plank in Auriga's aggressive business plan with the exclusive licensing of the Aquoral brand from France's Laboratories Carilene," Dr. John Faessel, editor of SmallCapInsights.com, which provides paid editorial coverage under compensation terms described below.
"Auriga's unique approach of acquiring or licensing established pharmaceutical brands, as well as its innovative drug development initiatives will, in our opinion, turn this smallcap into an investment to be reckoned with in relatively short order," added Dr. Faessel.
According to Mr. Pesin, licensing of the Aquoral(tm) brand furthers the Company's business plan to capitalize on high-growth opportunities in the pharmaceutical industry through aggressive sales, integrated marketing and application of proprietary in-house drug development capabilities.
To listen to the complete SmallCapInsights.com audio interview, visit http://www.smallcapinsights.com.
About Auriga Laboratories(tm)
Auriga Laboratories(tm) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities. The Company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The Company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive product portfolio currently includes the Extendryl(r) and Levall(r) families of prescription products, indicated for relief of symptoms associated with a range of acute respiratory diseases. Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the Company will seek to acquire and/or in-license additional products and technologies to further grow revenues. For more information, please visit: www.aurigalabs.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/auriga/. For an informational video overview, visit http://www.trilogy-capital.com/tcp/auriga/video.html. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/auriga/quote.html.
About SmallCapInsights.com
The editors and publishers of SmallCapInsights.com have decades of direct experience both in the markets and in the newsletter genre as well as being avid students of the sector. The Companies we illuminate and represent are those we feel have the best chance of enhancing portfolio returns as we take them from initial profile to ongoing in-depth coverage. We aren't married to any space within the smallcap sector, just to those ideas and strategies that will make our opinions and observations a relevant starting point to your complete and ongoing due diligence. The good, the bad and the bizarre -and hopefully profitable--will populate our pieces. Our readers will first and foremost be our priority. Every article will include a detailed disclaimer. We are not analysts, but rather view our picks as an investor might: questioning, commenting and delivering our best opinions, be they pro or con. As well, in each piece we will highlight a technical opinion, which, though it can never be definitive, will serve to give readers a quick snapshot of our current T/A thoughts. For more information, visit http://www.smallcapinsights.com.
Compensation Disclosures
Editorial is provided by SmallcapInsights.com ("Smallcap") to provide readers with information on publicly traded companies which have retained Smallcap to provide editorial commentary. Smallcap receives compensation for those services from the company, which consists of cash and/or securities of the company. Factual information is obtained from public filings and other sources deemed to be reliable; however, Smallcap takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete. Further, Smallcap and its employees and affiliates may own, or may purchase and sell, securities of the companies profiled. Smallcap undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled companies. As of September 11, 2006, SmallcapInsights.com receives from Auriga Laboratories an aggregate of US$21,500 for six months of editorial coverage.
Forward-Looking Statements
Certain of the statements in this website may be considered forwarded looking statements. Smallcap makes no representation and provides no assurance or guaranty that such forward looking statements will be prove to be accurate. Statements of opinion and belief are those of the authors and/or editors of this website, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the companies profiled or any particular expertise in the industries or markets in which the profiled companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of profiled companies. Neither Smallcap nor anyone involved in the publication of this editorial is a registered investment adviser or broker/dealer. Smallcap makes no recommendation that the purchase of securities of companies profiled in this editorial is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. An investor in such securities should be prepared and able to bear a loss of his or her entire investment. Nothing in this editorial should be construed as an offer or solicitation to buy or sell any securities of any profiled company.